Sutro Total Assets vs Net Working Capital Analysis

STRO Stock

USD 3.73 0.02 0.54%

Sutro Biopharma financial indicator trend analysis is much more than just breaking down Sutro Biopharma prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sutro Biopharma is a good investment. Please check the relationship between Sutro Biopharma Total Assets and its Net Working Capital accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sutro Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.

Total Assets vs Net Working Capital

Total Assets vs Net Working Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sutro Biopharma Total Assets account and Net Working Capital. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Sutro Biopharma's Total Assets and Net Working Capital is 0.98. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of Sutro Biopharma, assuming nothing else is changed. The correlation between historical values of Sutro Biopharma's Total Assets and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Sutro Biopharma are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Total Assets i.e., Sutro Biopharma's Total Assets and Net Working Capital go up and down completely randomly.

Correlation Coefficient

0.98

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Total Assets

Total assets refers to the total amount of Sutro Biopharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Sutro Biopharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Net Working Capital

Most indicators from Sutro Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sutro Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sutro Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.As of the 20th of October 2024, Sales General And Administrative To Revenue is likely to grow to 0.50, while Selling General Administrative is likely to drop about 41.3 M.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	9.8M	8.3M	6.8M	7.3M
Interest Income	577K	3.5M	12.1M	12.7M

Depreciation And Amortization Interest Income

Sutro Biopharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab
Total Assets		0.44	0.51	0.92	0.67	0.96	0.67	-0.02	0.14	-0.87	0.64	0.64	0.63	0.64	0.31	0.61	0.98	0.67	0.93	0.95	0.95	0.05	0.95	0.9	0.96	0.24
Other Current Liab	0.44		0.07	0.28	0.64	0.36	0.29	-0.43	0.63	-0.69	-0.06	0.19	0.16	-0.03	0.1	0.05	0.43	0.93	0.47	0.43	0.35	0.77	0.58	0.36	0.41	0.7
Total Current Liabilities	0.51	0.07		0.24	0.7	0.29	0.73	0.77	0.48	-0.63	0.86	-0.07	0.53	0.88	-0.12	-0.28	0.45	0.36	0.6	0.7	0.28	0.25	0.42	0.72	0.52	0.56
Total Stockholder Equity	0.92	0.28	0.24		0.45	0.99	0.48	-0.15	-0.12	-0.69	0.55	0.73	0.59	0.54	0.41	0.83	0.91	0.49	0.79	0.8	0.97	-0.24	0.91	0.77	0.89	-0.09
Other Liab	0.67	0.64	0.7	0.45		0.51	0.53	0.26	0.56	-0.88	0.6	0.28	0.36	0.68	-0.18	-0.06	0.66	0.82	0.65	0.76	0.49	0.56	0.72	0.73	0.61	0.75
Net Tangible Assets	0.96	0.36	0.29	0.99	0.51		0.52	-0.17	-0.04	-0.75	0.54	0.72	0.58	0.53	0.38	0.79	0.95	0.56	0.85	0.86	0.99	-0.15	0.93	0.81	0.92	0.0
Property Plant And Equipment Net	0.67	0.29	0.73	0.48	0.53	0.52		0.29	0.57	-0.75	0.76	-0.04	0.91	0.67	0.56	0.06	0.52	0.53	0.82	0.76	0.48	0.2	0.64	0.85	0.73	0.43
Current Deferred Revenue	-0.02	-0.43	0.77	-0.15	0.26	-0.17	0.29		0.14	-0.07	0.64	-0.26	0.18	0.66	-0.35	-0.47	-0.04	-0.19	0.04	0.18	-0.17	-0.04	-0.09	0.21	0.01	0.24
Net Debt	0.14	0.63	0.48	-0.12	0.56	-0.04	0.57	0.14		-0.58	0.3	-0.53	0.43	0.26	0.13	-0.52	0.01	0.67	0.4	0.34	-0.09	0.71	0.27	0.42	0.25	0.78
Retained Earnings	-0.87	-0.69	-0.63	-0.69	-0.88	-0.75	-0.75	-0.07	-0.58		-0.67	-0.33	-0.65	-0.67	-0.22	-0.24	-0.81	-0.9	-0.91	-0.91	-0.73	-0.43	-0.92	-0.91	-0.88	-0.62
Accounts Payable	0.64	-0.06	0.86	0.55	0.6	0.54	0.76	0.64	0.3	-0.67		0.1	0.76	0.98	0.17	0.09	0.56	0.3	0.71	0.76	0.51	-0.11	0.61	0.85	0.7	0.24
Cash	0.64	0.19	-0.07	0.73	0.28	0.72	-0.04	-0.26	-0.53	-0.33	0.1		-0.03	0.16	-0.05	0.78	0.76	0.26	0.34	0.41	0.77	-0.14	0.58	0.28	0.48	-0.12
Non Current Assets Total	0.63	0.16	0.53	0.59	0.36	0.58	0.91	0.18	0.43	-0.65	0.76	-0.03		0.64	0.75	0.26	0.46	0.4	0.76	0.67	0.51	-0.09	0.66	0.82	0.72	0.13
Non Currrent Assets Other	0.64	-0.03	0.88	0.54	0.68	0.53	0.67	0.66	0.26	-0.67	0.98	0.16	0.64		0.01	0.06	0.59	0.31	0.68	0.77	0.51	-0.08	0.6	0.83	0.67	0.27
Other Assets	0.31	0.1	-0.12	0.41	-0.18	0.38	0.56	-0.35	0.13	-0.22	0.17	-0.05	0.75	0.01		0.44	0.15	0.13	0.4	0.22	0.31	-0.25	0.35	0.35	0.38	-0.25
Long Term Debt	0.61	0.05	-0.28	0.83	-0.06	0.79	0.06	-0.47	-0.52	-0.24	0.09	0.78	0.26	0.06	0.44		0.64	0.12	0.43	0.38	0.8	-0.49	0.58	0.33	0.57	-0.49
Cash And Short Term Investments	0.98	0.43	0.45	0.91	0.66	0.95	0.52	-0.04	0.01	-0.81	0.56	0.76	0.46	0.59	0.15	0.64		0.64	0.85	0.91	0.96	0.05	0.92	0.81	0.91	0.22
Net Receivables	0.67	0.93	0.36	0.49	0.82	0.56	0.53	-0.19	0.67	-0.9	0.3	0.26	0.4	0.31	0.13	0.12	0.64		0.72	0.69	0.55	0.69	0.79	0.65	0.66	0.75
Common Stock Shares Outstanding	0.93	0.47	0.6	0.79	0.65	0.85	0.82	0.04	0.4	-0.91	0.71	0.34	0.76	0.68	0.4	0.43	0.85	0.72		0.97	0.84	0.14	0.91	0.96	0.98	0.34
Short Term Investments	0.95	0.43	0.7	0.8	0.76	0.86	0.76	0.18	0.34	-0.91	0.76	0.41	0.67	0.77	0.22	0.38	0.91	0.69	0.97		0.84	0.13	0.9	0.96	0.96	0.37
Long Term Debt Total	0.95	0.35	0.28	0.97	0.49	0.99	0.48	-0.17	-0.09	-0.73	0.51	0.77	0.51	0.51	0.31	0.8	0.96	0.55	0.84	0.84		-0.13	0.91	0.78	0.92	0.01
Non Current Liabilities Total	0.05	0.77	0.25	-0.24	0.56	-0.15	0.2	-0.04	0.71	-0.43	-0.11	-0.14	-0.09	-0.08	-0.25	-0.49	0.05	0.69	0.14	0.13	-0.13		0.14	0.08	0.02	0.94
Capital Surpluse	0.95	0.58	0.42	0.91	0.72	0.93	0.64	-0.09	0.27	-0.92	0.61	0.58	0.66	0.6	0.35	0.58	0.92	0.79	0.91	0.9	0.91	0.14		0.88	0.94	0.31
Other Current Assets	0.9	0.36	0.72	0.77	0.73	0.81	0.85	0.21	0.42	-0.91	0.85	0.28	0.82	0.83	0.35	0.33	0.81	0.65	0.96	0.96	0.78	0.08	0.88		0.94	0.34
Other Stockholder Equity	0.96	0.41	0.52	0.89	0.61	0.92	0.73	0.01	0.25	-0.88	0.7	0.48	0.72	0.67	0.38	0.57	0.91	0.66	0.98	0.96	0.92	0.02	0.94	0.94		0.22
Total Liab	0.24	0.7	0.56	-0.09	0.75	0.0	0.43	0.24	0.78	-0.62	0.24	-0.12	0.13	0.27	-0.25	-0.49	0.22	0.75	0.34	0.37	0.01	0.94	0.31	0.34	0.22

Click cells to compare fundamentals

Sutro Biopharma Account Relationship Matchups

Sutro Biopharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	156.4M	394.1M	341.4M	406.9M	470.7M	289.1M
Other Current Liab	6.9M	627K	14.5M	(17.1M)	53.2M	55.8M
Total Current Liabilities	33.0M	29.6M	41.7M	139.5M	93.7M	62.7M
Total Stockholder Equity	97.8M	332.0M	252.6M	217.0M	149.6M	134.9M
Other Liab	16.7M	7.9M	146K	90.0M	103.5M	108.7M
Net Tangible Assets	97.8M	332.0M	252.6M	217.0M	249.6M	130.6M
Property Plant And Equipment Net	9.6M	12.9M	51.6M	51.1M	44.8M	29.4M
Current Deferred Revenue	19.5M	14.6M	5.5M	106.6M	20.7M	33.4M
Net Debt	4.9M	(181.6M)	27.0M	20.3M	113.5M	119.2M
Retained Earnings	(195.7M)	(227.9M)	(333.4M)	(452.6M)	(559.4M)	(531.4M)
Accounts Payable	5.6M	5.5M	11.3M	32.8M	9.4M	10.2M
Cash	5.0M	206.2M	30.4M	47.3M	69.3M	71.1M
Non Current Assets Total	27.8M	15.9M	122.9M	97.5M	49.2M	49.7M
Non Currrent Assets Other	2.6M	2.1M	2.5M	14.4M	4.4M	4.2M
Other Assets	2.6M	3.0M	122.9M	2.7M	3.1M	3.0M
Long Term Debt	8.9M	24.5M	15.7M	3.8M	4.3M	4.1M
Cash And Short Term Investments	117.9M	368.1M	197.9M	302.3M	375.6M	224.9M
Net Receivables	6.3M	5.6M	12.5M	7.1M	36.1M	37.9M
Common Stock Shares Outstanding	23.0M	32.6M	46.1M	50.7M	60.2M	31.9M
Short Term Investments	112.9M	162.0M	167.5M	287.1M	306.4M	158.3M
Long Term Debt Total	10M	8.9M	24.5M	15.7M	18.1M	11.4M
Liabilities And Stockholders Equity	156.4M	394.1M	341.4M	406.9M	470.7M	289.1M
Non Current Liabilities Total	25.6M	32.5M	47.1M	50.4M	227.3M	238.7M
Capital Surpluse	281.9M	293.3M	559.7M	586.2M	674.2M	707.9M
Other Current Assets	4.4M	4.5M	8.1M	11.7M	9.8M	6.2M
Other Stockholder Equity	293.3M	559.7M	586.2M	670.2M	709.0M	397.1M
Total Liab	58.6M	62.1M	88.8M	189.9M	321.1M	337.1M
Property Plant And Equipment Gross	9.6M	12.9M	85.0M	51.1M	86.9M	91.3M
Total Current Assets	128.6M	378.2M	218.5M	309.5M	421.5M	239.5M
Accumulated Other Comprehensive Income	165K	129K	(314K)	(618K)	21K	22.1K
Non Current Liabilities Other	134K	481K	146K	119K	1.7M	1.8M
Short Term Debt	1M	8.8M	10.4M	17.1M	10.5M	9.7M
Property Plant Equipment	9.6M	12.9M	51.6M	51.1M	58.7M	61.7M
Short Long Term Debt Total	9.9M	33.4M	57.4M	67.5M	182.7M	191.9M
Net Invested Capital	107.7M	356.6M	277.7M	233.3M	153.7M	185.6M
Short Long Term Debt	4.7M	1M	9.4M	12.5M	4.1M	6.2M
Net Working Capital	95.6M	348.6M	176.8M	286.6M	327.8M	220.4M

Pair Trading with Sutro Biopharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sutro Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sutro Biopharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Sutro Stock

0.44	LPCN	Lipocine	Pair Corr
0.36	GNFT	Genfit	Pair Corr

The ability to find closely correlated positions to Sutro Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sutro Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sutro Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sutro Biopharma to buy it.

The correlation of Sutro Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sutro Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sutro Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Sutro Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Sutro Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sutro Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sutro Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sutro Biopharma Stock:

How To Invest In Sutro

Details

Is Sutro Stock a good investment?

Details

What is Sutro Biopharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sutro Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.

You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sutro Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.78)

Revenue Per Share

2.563

Quarterly Revenue Growth

1.469

Return On Assets

(0.14)

Return On Equity

(0.81)

The market value of Sutro Biopharma is measured differently than its book value, which is the value of Sutro that is recorded on the company's balance sheet. Investors also form their own opinion of Sutro Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sutro Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sutro Biopharma's market value can be influenced by many factors that don't directly affect Sutro Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sutro Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Sutro Total Assets vs Net Working Capital Analysis

Total Assets vs Net Working Capital

Total Assets vs Net Working Capital Correlation Analysis

Correlation Coefficient

Total Assets

Net Working Capital

Sutro Biopharma fundamental ratios Correlations

Sutro Biopharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Sutro Biopharma fundamental ratios Accounts

Pair Trading with Sutro Biopharma

Moving against Sutro Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Tangible Assets	+ 0.99	Total Stockholder Equity
Long Term Debt Total	+ 0.99	Net Tangible Assets
Cash And Short Term Investments	+ 0.98	Total Assets
Non Currrent Assets Other	+ 0.98	Accounts Payable
Other Stockholder Equity	+ 0.98	Common Stock Shares Outstanding
Long Term Debt Total	+ 0.97	Total Stockholder Equity

Capital Surpluse	- 0.92	Retained Earnings
Other Current Assets	- 0.91	Retained Earnings
Short Term Investments	- 0.91	Retained Earnings
Common Stock Shares Outstanding	- 0.91	Retained Earnings
Net Receivables	- 0.9	Retained Earnings
Other Stockholder Equity	- 0.88	Retained Earnings